Gapping up
In reaction to strong earnings/guidance: HAS +8.2%, SVA +6.4%, CHKP +2.4%, MS +2%, LII +1.6%, HAL +0.4%
M&A news: PLD +2.6% (signs definitive agreements to acquire $5.9 bln portfolio from KTR Capital Partners; also rpted earnings)
Select metals/mining stocks trading higher: GFI +3%, FSM +2.9%, HMY +2.6%, RIO +0.8%, BHP +0.5%
Other news: GENE +25.8% (announces additional breast health centres to begin offering BREVAGenplus), PVCT +11.1% (Provectus Pharma and Pfizer (PFE) announce receipt of Patent Allowance for Use of PV-10 for the treatment of cancer), HQCL +8.8% (announces over 1.5 GW solar module supply agreement to power NextEra Energy Resources' (NEE) continued solar investments in the U.S.), CYCC +6.9% (announces pre-clinical data from its Second-Generation CDK2/9 inhibitor), ONCY +6.4% (announces that a series of poster presentations by its research collaborators will be made at the 2015 AACR), VPCO +6.3% (files for ~6.2 mln share common stock offering by selling shareholders), ROVI +6.3% (announces it has renewed its patent license and interactive program guide product agreement with Charter Communications), NBS +4.6% (announces the expansion of manufacturing services under an existing Services Agreement between its subsidiary and Kite Pharma (KITE)), FNRG +4.5% (founder and majority shareholder Richard St-Julien voluntarily resigned as the Company's Executive Chairman of the Board, and from all other positions he held with the company; also issues business update; divested its interest in Trans Pacific Energy and its TCS business), CLDX +3.7% (announces preclinical results that further support varlilumab's expansion into combination studies with PD-1 inhibitors), URI +2.1% (Barron's profiles positive view), TASR +2.1% (announces that the Ontario Provincial Police has purchased 1000 Taser X2 smart weapons), PBR +1.7% (announced the concluded negotiations on various loan contracts), HZNP +1.6% (announces proposed private offering of senior notes and intention to enter into new term loan facility), ABBV +1.5% (extends exchange offer to acquire Pharmacyclics (PCYC) to May 1, 2015), CHRS +1.4% (obtained positive results of a repeat Phase 1 pharmacokinetic bioequivalence study for CHS-0214, its etanercept biosimilar candidate), MAT +1.4% (in sympathy with HAS earnings), ING +1.3% (still checking), COST +1.2% (announces reauthorization of $4 bln stock repurchase program; increases quarterly dividend 12.7% to $0.40 from $0.355 per share), MRK +1% (announces submission of supplemental Biologics License Application to FDA for KEYTRUDA in advanced non-small cell lung cancer), MNTA +0.9% (presents new data from studies conducted as part of the ANDA submission for once daily Glatopa)
Analyst comments: ADRO +9% (initiated with a Buy at ROTH Capital; tgt $74), SEDG +3.4% (initiated with a Buy at Goldman; initiated with a Buy at Deutsche Bank), CLLS +3.1% (initiated with a Overweight at Piper Jaffray), CUBE +2.9% (upgraded to Buy from Hold at Evercore ISI), MTG +2.7% (upgraded to Neutral from Underperform at Credit Suisse), BCRX +2.7% (upgraded to Neutral from Underperform at BofA/Merrill), SPLK +1.7% (initiated with a Buy at Citigroup), JBHT +1.7% (upgraded to Buy from Underperform at BofA/Merrill), CPLP +1.7% (upgraded to Buy from Neutral at BofA/Merrill), GIS +1.6% (upgraded to Neutral from Sell at Goldman), HSBC +1.5% (added to Conviction Buy List at Goldman), FB +1.1% (favorable commentary at Oppenheimer),UN +0.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts), JNJ +0.5% (added to Short-Term Buy List at Deutsche Bank
)
In reaction to strong earnings/guidance: HAS +8.2%, SVA +6.4%, CHKP +2.4%, MS +2%, LII +1.6%, HAL +0.4%
M&A news: PLD +2.6% (signs definitive agreements to acquire $5.9 bln portfolio from KTR Capital Partners; also rpted earnings)
Select metals/mining stocks trading higher: GFI +3%, FSM +2.9%, HMY +2.6%, RIO +0.8%, BHP +0.5%
Other news: GENE +25.8% (announces additional breast health centres to begin offering BREVAGenplus), PVCT +11.1% (Provectus Pharma and Pfizer (PFE) announce receipt of Patent Allowance for Use of PV-10 for the treatment of cancer), HQCL +8.8% (announces over 1.5 GW solar module supply agreement to power NextEra Energy Resources' (NEE) continued solar investments in the U.S.), CYCC +6.9% (announces pre-clinical data from its Second-Generation CDK2/9 inhibitor), ONCY +6.4% (announces that a series of poster presentations by its research collaborators will be made at the 2015 AACR), VPCO +6.3% (files for ~6.2 mln share common stock offering by selling shareholders), ROVI +6.3% (announces it has renewed its patent license and interactive program guide product agreement with Charter Communications), NBS +4.6% (announces the expansion of manufacturing services under an existing Services Agreement between its subsidiary and Kite Pharma (KITE)), FNRG +4.5% (founder and majority shareholder Richard St-Julien voluntarily resigned as the Company's Executive Chairman of the Board, and from all other positions he held with the company; also issues business update; divested its interest in Trans Pacific Energy and its TCS business), CLDX +3.7% (announces preclinical results that further support varlilumab's expansion into combination studies with PD-1 inhibitors), URI +2.1% (Barron's profiles positive view), TASR +2.1% (announces that the Ontario Provincial Police has purchased 1000 Taser X2 smart weapons), PBR +1.7% (announced the concluded negotiations on various loan contracts), HZNP +1.6% (announces proposed private offering of senior notes and intention to enter into new term loan facility), ABBV +1.5% (extends exchange offer to acquire Pharmacyclics (PCYC) to May 1, 2015), CHRS +1.4% (obtained positive results of a repeat Phase 1 pharmacokinetic bioequivalence study for CHS-0214, its etanercept biosimilar candidate), MAT +1.4% (in sympathy with HAS earnings), ING +1.3% (still checking), COST +1.2% (announces reauthorization of $4 bln stock repurchase program; increases quarterly dividend 12.7% to $0.40 from $0.355 per share), MRK +1% (announces submission of supplemental Biologics License Application to FDA for KEYTRUDA in advanced non-small cell lung cancer), MNTA +0.9% (presents new data from studies conducted as part of the ANDA submission for once daily Glatopa)
Analyst comments: ADRO +9% (initiated with a Buy at ROTH Capital; tgt $74), SEDG +3.4% (initiated with a Buy at Goldman; initiated with a Buy at Deutsche Bank), CLLS +3.1% (initiated with a Overweight at Piper Jaffray), CUBE +2.9% (upgraded to Buy from Hold at Evercore ISI), MTG +2.7% (upgraded to Neutral from Underperform at Credit Suisse), BCRX +2.7% (upgraded to Neutral from Underperform at BofA/Merrill), SPLK +1.7% (initiated with a Buy at Citigroup), JBHT +1.7% (upgraded to Buy from Underperform at BofA/Merrill), CPLP +1.7% (upgraded to Buy from Neutral at BofA/Merrill), GIS +1.6% (upgraded to Neutral from Sell at Goldman), HSBC +1.5% (added to Conviction Buy List at Goldman), FB +1.1% (favorable commentary at Oppenheimer),UN +0.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts), JNJ +0.5% (added to Short-Term Buy List at Deutsche Bank
)